|
1
|
Okano H, Kawahara H, Toriya M, Nakao K,
Shibata S and Imai T: Function of RNA-binding protein Musashi-1 in
stem cells. Exp Cell Res. 306:349–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sutherland JM, McLaughlin EA, Hime GR and
Siddall NA: The Musashi family of RNA binding proteins: Master
regulators of multiple stem cell populations. Adv Exp Med Biol.
786:233–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang S, Li N, Yousefi M, Nakauka-Ddamba A,
Li F, Parada K, Rao S, Minuesa G, Katz Y, Gregory BD, et al:
Transformation of the intestinal epithelium by the MSI2 RNA-binding
protein. Nat Commun. 6:65172015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kharas MG, Lengner CJ, Al-Shahrour F,
Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R,
et al: Musashi-2 regulates normal hematopoiesis and promotes
aggressive myeloid leukemia. Nat Med. 16:903–908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Griner LN and Reuther GW: Aggressive
myeloid leukemia formation is directed by the Musashi 2/Numb
pathway. Cancer Biol Ther. 10:979–982. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mu Q, Wang Y, Chen B, Qian W, Meng H, Tong
H, Chen F, Ma Q, Ni W, Chen S, et al: High expression of Musashi-2
indicates poor prognosis in adult B-cell acute lymphoblastic
leukemia. Leuk Res. 37:922–927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He L, Zhou X, Qu C, Hu L, Tang Y, Zhang Q,
Liang M and Hong J: Musashi2 predicts poor prognosis and invasion
in hepatocellular carcinoma by driving epithelial-mesenchymal
transition. J Cell Mol Med. 18:49–58. 2014. View Article : Google Scholar
|
|
8
|
Sakakibara S, Nakamura Y, Satoh H and
Okano H: RNA-binding protein Musashi2: Developmentally regulated
expression in neural precursor cells and subpopulations of neurons
in mammalian CNS. J Neurosci. 21:8091–8107. 2001.PubMed/NCBI
|
|
9
|
Imai T, Tokunaga A, Yoshida T, Hashimoto
M, Mikoshiba K, Weinmaster G, Nakafuku M and Okano H: The neural
RNA-binding protein Musashi1 translationally regulates mammalian
numb gene expression by interacting with its mRNA. Mol Cell Biol.
21:3888–3900. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Battelli C, Nikopoulos GN, Mitchell JG and
Verdi JM: The RNA-binding protein Musashi-1 regulates neural
development through the translational repression of p21WAF-1. Mol
Cell Neurosci. 31:85–96. 2006. View Article : Google Scholar
|
|
11
|
Zhang H, Tan S, Wang J, Chen S, Quan J,
Xian J, Zhang S, He J and Zhang L: Musashi2 modulates K562 leukemic
cell proliferation and apoptosis involving the MAPK pathway. Exp
Cell Res. 320:119–127. 2014. View Article : Google Scholar
|
|
12
|
Han Y, Ye A, Zhang Y, Cai Z, Wang W, Sun
L, Jiang S, Wu J, Yu K and Zhang S: Musashi-2 silencing exerts
potent activity against acute myeloid leukemia and enhances
chemosensitivity to daunorubicin. PLoS One. 10:e01364842015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
14
|
Razi S, Ghoncheh M, Mohammadian-Hafshejani
A, Aziznejhad H, Mohammadian M and Salehiniya H: The incidence and
mortality of ovarian cancer and their relationship with the Human
Development Index in Asia. E Cancer Med Sci. 10:6282016.
|
|
15
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar :
|
|
17
|
Schorge JO, McCann C and Del Carmen MG:
Surgical debulking of ovarian cancer: What difference does it make?
Rev Obstet Gynecol. 3:111–117. 2010.
|
|
18
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McGuire WP and Ozols RF: Chemotherapy of
advanced ovarian cancer. Semin Oncol. 25:340–348. 1998.PubMed/NCBI
|
|
20
|
Sherman-Baust CA, Becker KG, Wood Iii WH,
Zhang Y and Morin PJ: Gene expression and pathway analysis of
ovarian cancer cells selected for resistance to cisplatin,
paclitaxel, or doxorubicin. J Ovarian Res. 4:212011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakayama K, Nakayama N, Jinawath N, Salani
R, Kurman RJ, Shih IeM and Wang TL: Amplicon profiles in ovarian
serous carcinomas. Int J Cancer. 120:2613–2617. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cox JL, Wilder PJ, Gilmore JM, Wuebben EL,
Washburn MP and Rizzino A: The SOX2-interactome in brain cancer
cells identifies the requirement of MSI2 and USP9X for the growth
of brain tumor cells. PLoS One. 8:e628572013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ledermann JA and Kristeleit RS: Optimal
treatment for relapsing ovarian cancer. Ann Oncol. 21(Suppl 7):
vii218–vii222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhan Q, Wang C and Ngai S: Ovarian cancer
stem cells: A new target for cancer therapy. BioMed Res Int.
2013:9168192013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mechetner E, Kyshtoobayeva A, Zonis S, Kim
H, Stroup R, Garcia R, Parker RJ and Fruehauf JP: Levels of
multidrug resistance (MDR1) P-glycoprotein expression by human
breast cancer correlate with in vitro resistance to taxol and
doxorubicin. Clin Cancer Res. 4:389–398. 1998.PubMed/NCBI
|
|
26
|
Duan Z, Brakora KA and Seiden MV:
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small
interfering RNA and reversal of paclitaxel resistance in human
ovarian cancer cells. Mol Cancer Ther. 3:833–838. 2004.PubMed/NCBI
|
|
27
|
Horwitz SB, Cohen D, Rao S, Ringel I, Shen
HJ and Yang CP: Taxol: Mechanisms of action and resistance. J Natl
Cancer Inst Monogr. 15:55–61. 1993.PubMed/NCBI
|
|
28
|
Colombo N, Peiretti M, Parma G, Lapresa M,
Mancari R, Carinelli S, Sessa C and Castiglione M; ESMO Guidelines
Working Group. Newly diagnosed and relapsed epithelial ovarian
carcinoma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 21(Suppl 5): v23–v30. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ozols RF: Recurrent ovarian cancer:
Evidence-based treatment. J Clin Oncol. 20:1161–1163.
2002.PubMed/NCBI
|
|
30
|
Fox RG, Lytle NK, Jaquish DV, Park FD, Ito
T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp JL, et al:
Image-based detection and targeting of therapy resistance in
pancreatic adenocarcinoma. Nature. 534:407–411. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goda K, Bacsó Z and Szabó G: Multidrug
resistance through the spectacle of P-glycoprotein. Curr Cancer
Drug Targets. 9:281–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
